Save the Date: International CNS-GCT Conference

Joint event of the University Hospital Bonn and University Hospital Essen!

Due to the rarity of intracranial germ cell tumors, an interdisciplinary, international network with specialist associations was established very early on to ensure the best possible treatment for patients.

We are delighted to be hosting this international germ cell tumour meeting 2025 in Germany for the first time!

In recent years, many new findings on this disease entity have been collected and published. The focus has been on the effect of radiotherapy and the possibilities of dose reduction, treatment options for high-risk patients and the use of new biomarkers such as microRNA. The results of the European SIOP CNS GCT 96 and SIOP GCT II study, which was conducted by the German Group, lead by Dr. Gabriele Calaminus, have made an important contribution to this. We would now like to take the opportunity to invite the international specialist community to Germany during the planning and development phase of a follow-up protocol for children and adolescents with germ cell tumours and to contribute to a worldwide transfer of knowledge on this rare type of tumour at this symposium. It is also our aim to make the reference centres for the diagnosis and treatment of brain tumours implemented in Germany internationally visible.

We chose Essen as the venue for the event, firstly to demonstrate the importance to the radiotherapy reference centre, but also because Prof. Timmermann and her team are the leading reference radiotherapy consultants for CNS germ cell tumour patients, who work closely together with Dr. Calaminus and her team at the Paediatric Oncology Reference Centre for Germ Cell tumors in Bonn.

Venue:

The event will take place at the University Hospital Essen, „Haus der Technik“ in Essen.

Registration:

Please register by August 4, 2025 using the registration form here

Conference fee:                     200,00 EUR

Dinner fee (optional):           50,00 EUR

The event is organized by the Brain Tumor Group of The European Society for Paediatric Oncology (SIOPE) together with the University Hospital Bonn and the University Hospital Essen.